Prospects for combined use of oncolytic viruses and CAR T-cells

Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer

(2017) W Zhou et al.   GENE THERAPY

AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1

(2017) S.S. Neelapu et al.   HEMATOLOGICAL ONCOLOGY

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS

(2017) S.J. Schuster et al.   HEMATOLOGICAL ONCOLOGY

Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle

(2017) Christiane Dinsart et al.   HUMAN GENE THERAPY

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

(2017) James N. Kochenderfer et al.   MOLECULAR THERAPY

Novel Use of All-Trans-Retinoic Acid in A Model of Lipopolysaccharide-Immunosuppression to Decrease the Generation of Myeloid-Derived Suppressor Cells by Reducing the Proliferation of CD34+ Precursor Cells

(2017) Daiana Martire-Greco et al.   SHOCK

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

(2017) Melinda Mata et al.   Cancer Discovery

Global Manufacturing of CAR T Cell Therapy

(2017) Bruce L. Levine et al.   Molecular Therapy-Methods & Clinical Development

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers

(2017) Assia L. Angelova et al.   Frontiers in Oncology

The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients

(2016) Zhenqian Wu et al.   BIOMEDICINE & PHARMACOTHERAPY

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

(2016) Holger Bronger et al.   BRITISH JOURNAL OF CANCER

Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy

(2016) Weizhou Hou et al.   CANCER CELL

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis

(2016) Tianli Xia et al.   CANCER RESEARCH

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

(2016) Kole T. Roybal et al.   CELL

Driving gene-engineered T cell immunotherapy of cancer

(2016) Laura A Johnson et al.   CELL RESEARCH

Innate immune signaling and regulation in cancer immunotherapy

(2016) Leticia Corrales et al.   CELL RESEARCH

Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators

(2016) Hilmar Weinmann   ChemMedChem

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

(2016) Min Zhu et al.   CLINICAL PHARMACOKINETICS

Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer

(2016) Chuan Jin et al.   EMBO Molecular Medicine

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

Single versus combination immunotherapy drug treatment in melanoma

(2016) Antonio Maria Grimaldi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment

(2016) E Eriksson et al.   GENE THERAPY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

(2016) Aung Naing et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography

(2016) Amer M. Najjar et al.   MOLECULAR IMAGING AND BIOLOGY

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

(2016) Stephanie Downs-Canner et al.   MOLECULAR THERAPY

515. Oncolytic Adenovirus Armed with Cytokines Enhances CAR-T Cell Efficacy in Pancreatic Tumor Model

(2016) Keisuke Watanabe et al.   MOLECULAR THERAPY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma

(2016) H Gurler Main et al.   ONCOGENE

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

(2016) Kevin Cassady et al.   Viruses-Basel

Oncolytic viruses as immunotherapy: progress and remaining challenges

(2016) Laure Aurelian   OncoTargets and Therapy

The oncolytic peptide LTX-315 triggers immunogenic cell death

(2016) H Zhou et al.   Cell Death & Disease

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

(2016) M Cartellieri et al.   Blood Cancer Journal

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer

(2016) Yu-Jie Zeng et al.   Oncotarget

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

(2016) Tianli Xia et al.   Cell Reports

Bioinformatics Analysis of the Human Surfaceome Reveals New Targets for a Variety of Tumor Types

(2016) André L. Fonseca et al.   International Journal of Genomics

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization

(2016) K. Newick et al.   Cancer Immunology Research

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas

(2016) A. H. Long et al.   Cancer Immunology Research

CXCL9: evidence and contradictions for its role in tumor progression

(2016) Qiang Ding et al.   Cancer Medicine

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

(2016) Patricia Kleinpeter et al.   OncoImmunology

Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity?

(2016) David Marc Davies et al.   Translational Cancer Research

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy

(2016) Marcin P Komorowski et al.   Molecular Therapy-Oncolytics

CAR models: next-generation CAR modifications for enhanced T-cell function

(2016) Daniel Abate-Daga et al.   Molecular Therapy-Oncolytics

A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity

(2016) Kaname Nosaki et al.   Molecular Therapy-Oncolytics

Chimeric antigen receptor T-cell therapy for solid tumors

(2016) Kheng Newick et al.   Molecular Therapy-Oncolytics

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors

(2016) Krijn K. Dijkstra et al.   JAMA Oncology

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

(2016) Imran Siddiqui et al.   Journal for ImmunoTherapy of Cancer

Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy

(2016) Anthony Visioni et al.   Cancers

Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus

(2015) Chang Yoon Moon et al.   BIOMATERIALS

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Towards a commercial process for the manufacture of genetically modified T cells for therapy

(2015) A D Kaiser et al.   CANCER GENE THERAPY

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy

(2015) J. J. Rojas et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Genetically modified T cells in cancer therapy: opportunities and challenges

(2015) M. Sharpe et al.   Disease Models & Mechanisms

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic Adenovirus

(2015) Mari Hirvinen et al.   HUMAN GENE THERAPY

Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L

(2015) Guang-yao Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts

(2015) SIMENG WEN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model

(2015) Youjin Na et al.   JOURNAL OF CONTROLLED RELEASE

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

(2015) Laura Evgin et al.   MOLECULAR THERAPY

Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression

(2015) Kevin J Curran et al.   MOLECULAR THERAPY

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

(2015) Carolina S Ilkow et al.   NATURE MEDICINE

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma

(2015) Shannon K. Quirk et al.   Translational Research

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

(2015) Manish R. Patel et al.   Oncotarget

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

(2015) R. Houot et al.   Cancer Immunology Research

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

(2015) S. Tahtinen et al.   Cancer Immunology Research

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

(2015) Nobuhiro Nishio et al.   OncoImmunology

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer

(2015) Louisa S Chard et al.   OncoImmunology

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

(2015) Zuqiang Liu et al.   OncoImmunology

Toward the identification of genetic determinants of breast cancer immune responsiveness

(2015) Ines Simeone et al.   Journal for ImmunoTherapy of Cancer

Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression

(2015) Galina Kochneva et al.   Oncotarget

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

(2015) Xinping Fu et al.   Oncotarget

Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity

(2015) Jun Li et al.   NEOPLASIA

Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity

(2014) Jason W. Griffith et al.   Annual Review of Immunology

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy

(2014) Fu-Liang Bai et al.   CANCER BIOLOGY & THERAPY

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

(2014) V. Roulstone et al.   CLINICAL CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

CXCR3+CCR5+ T cells and autoimmune diseases: guilty as charged?

(2014) Charles R. Mackay   JOURNAL OF CLINICAL INVESTIGATION

Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus

(2014) Elizabeth Ilett et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

TNF-related Apoptosis-inducing Ligand Delivered by rNDV is a Novel Agent for Cancer Gene Therapy

(2014) Fu-Liang Bai et al.   TECHNOLOGY IN CANCER RESEARCH & TREATMENT

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

(2013) D. Abate-Daga et al.   BLOOD

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling

(2013) Y Yu et al.   BRITISH JOURNAL OF CANCER

Inhibitors of C5 complement enhance vaccinia virus oncolysis

(2013) D Magge et al.   CANCER GENE THERAPY

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?

(2013) Walter H Meisen et al.   Expert Review of Neurotherapeutics

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

The Oncolytic Activity of Newcastle Disease Virus in Clear Cell Renal Carcinoma Cells in Normoxic and Hypoxic Conditions: The Interplay Between von Hippel-Lindau and Interferon-β Signaling

(2013) Wei-Choong Ch'ng et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy

(2013) Feng Yu et al.   MOLECULAR THERAPY

Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis

(2013) Greg M. Delgoffe et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

A Self-Help Program for Memory CD8+ T Cells: Positive Feedback via CD40-CD40L Signaling as a Critical Determinant of Secondary Expansion

(2013) Jessica A. Shugart et al.   PLoS One

Serum CXCL9 Levels Are Associated with Tumor Progression and Treatment Outcome in Patients with Nasopharyngeal Carcinoma

(2013) Li-Jen Hsin et al.   PLoS One

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Update on oncolytic viral therapy – targeting angiogenesis

(2013) James Tysome et al.   OncoTargets and Therapy

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

(2013) May C.I. van Schalkwyk et al.   Human Gene Therapy Clinical Development

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs

(2012) J. Emmerich et al.   CANCER RESEARCH

A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity

(2012) J. R. Tysome et al.   CLINICAL CANCER RESEARCH

Clinical Development of Oncolytic Viruses in China

(2012) Min Liang   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

AdCD40L—Crossing the Valley of Death?

(2012) Gustav Ullenhag et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Compensatory dendritic cell development mediated by BATF–IRF interactions

(2012) Roxane Tussiwand et al.   NATURE

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Signal 3 Cytokines as Modulators of Primary Immune Responses during Infections: The Interplay of Type I IFN and IL-12 in CD8 T Cell Responses

(2012) Selina Jessica Keppler et al.   PLoS One

The pros and cons of chemokines in tumor immunology

(2012) Antonella Viola et al.   TRENDS IN IMMUNOLOGY

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells

(2011) N. Obermajer et al.   BLOOD

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer

(2011) Philippe A Cassier et al.   BMC CANCER

Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation

(2011) S Yamada et al.   CANCER GENE THERAPY

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

CXCR3 in T cell function

(2011) Joanna R. Groom et al.   EXPERIMENTAL CELL RESEARCH

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

(2011) J D Dias et al.   GENE THERAPY

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα

(2011) I-K Choi et al.   GENE THERAPY

Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes

(2011) Anna Korniejewska et al.   IMMUNOLOGY

Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice

(2011) Ana Caterina Parente-Pereira et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells

(2011) M. Mansour et al.   JOURNAL OF VIROLOGY

Oncolytic Herpes Simplex Virus 1 Encoding 15-Prostaglandin Dehydrogenase Mitigates Immune Suppression and Reduces Ectopic Primary and Metastatic Breast Cancer in Mice

(2011) J. D. Walker et al.   JOURNAL OF VIROLOGY

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

(2011) Ling Zhang et al.   MOLECULAR THERAPY

Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer

(2011) Jun Li et al.   MOLECULAR THERAPY

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells

(2011) Dat Q. Tran   Journal of Molecular Cell Biology

IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice

(2010) J. C. Markley et al.   BLOOD

Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

(2010) J. Mitsui et al.   CLINICAL CANCER RESEARCH

CD40L co-stimulation from CD8+ to CD4+ effector memory T cells supports CD4+ expansion

(2010) Maria Xydia et al.   IMMUNOLOGY AND CELL BIOLOGY

Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

(2010) Sonia Guedan et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand

(2009) H. S. Kim et al.   CANCER RESEARCH

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

Tumor Associated Stromal Cells Play a Critical Role on the Outcome of the Oncolytic Efficacy of Conditionally Replicative Adenoviruses

(2009) M. Verónica Lopez et al.   PLoS One

Ras Signaling Influences Permissiveness of Malignant Peripheral Nerve Sheath Tumor Cells to Oncolytic Herpes

(2008) Faris Farassati et al.   AMERICAN JOURNAL OF PATHOLOGY

Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion

(2008) D. H. Kirn et al.   CANCER RESEARCH

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

(2008) J. L. Gulley et al.   CLINICAL CANCER RESEARCH

Treg Depletion–enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus

(2008) Timothy Kottke et al.   MOLECULAR THERAPY

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE

ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer

(2008) Weiguo Chen et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS